{"entity":{"id":"infliximab","kind":"drug","name":"Infliximab","aka":[],"tldr":"Infliximab is an anti-inflammatory drip used for Crohn's disease and arthritis. When checkpoint immunotherapy causes colitis that steroids do not control, it is the usual next step; it is avoided for immune hepatitis.","summary":"The Remicade label covers Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. SITC 2021: if colitis does not respond to corticosteroids within 3 to 5 days, recurs on the taper, or is severely ulcerative at colonoscopy, \"3 doses of infliximab (5 mg/kg) should be administered at 0, 2, and 6 weeks\" (LE 1); people should be tested for hepatitis B, HIV and tuberculosis first without delaying the dose; and \"Infliximab should not be used in patients with liver toxicity, given the risk for hepatotoxicity\". SITC also names it for steroid-refractory nephritis and pneumonitis. The BLA was first approved on 24 August 1998.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Infliximab","links":[{"label":"US label (DailyMed): Remicade","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0a046c1-056d-45a9-bfd9-13b47c24f257"},{"label":"Brahmer et al., SITC clinical practice guideline on immune checkpoint inhibitor-related adverse events (J Immunother Cancer 2021)","url":"https://doi.org/10.1136/jitc-2021-002435"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":["vedolizumab","mycophenolate"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["immune-colitis","irae","pneumonitis"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Remicade","modality":"Monoclonal antibody (TNF blocker)","supportive":true,"mechanism":"A chimeric monoclonal antibody that binds and blocks tumour necrosis factor alpha.","approvals":[{"region":"US","year":1998,"indication":"Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis","note":"Year is the original BLA 103772 approval (Drugs@FDA); immune-related colitis is off-label"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/infliximab/","neighbours":{"drug":[{"id":"mycophenolate","kind":"drug","name":"Mycophenolate mofetil","route":"/drugs/mycophenolate/"},{"id":"vedolizumab","kind":"drug","name":"Vedolizumab","route":"/drugs/vedolizumab/"}],"term":[{"id":"immune-colitis","kind":"term","name":"Immune-mediated colitis and diarrhoea","route":"/terms/immune-colitis/"},{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/"},{"id":"pneumonitis","kind":"term","name":"Pneumonitis","route":"/terms/pneumonitis/"}]}}